---
figid: PMC4209854__emss-60583-f0003
figtitle: 'Targeting EGFR signalling in chronic lung disease: therapeutic challenges
  and opportunities'
organisms:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Macaca mulatta
- Nicotiana tabacum
- Pseudomonas aeruginosa
pmcid: PMC4209854
filename: emss-60583-f0003.jpg
figlink: /pmc/articles/PMC4209854/figure/F3/
number: F3
caption: 'Three strategies are used to antagonise aberrant EGFR signalling. First,
  monoclonal antibodies bind the extracellular domain of epidermal growth factor (EGF)
  receptors and prevent endogenous ligand engagement, thereby attenuating downstream
  pathway activation (cetuximab and trastuzumab). Secondly, small molecule tyrosine
  kinase inhibitors target the intracellular portion of EGF receptors; in the absence
  of kinase activity EGFR autophosphorylation and downstream signalling is inhibited
  (erlotinib, gefitinib, lapatinib, HKI-272 and BIBW-2948). Finally, small molecule
  inhibitors which target specific downstream EGFR signalling pathway components have
  also been developed and may exhibit clinical efficacy in chronic respiratory disease
  (ARRY-142886, PX-866, rapamycin, SDZ RAD, everolimus, ruxolitinib, perifosine, selumetinib
  and sorafenib). PI3K: phosphatidylinositol-3-kinase; PIP3: phosphatidylinositol
  (3,4,5)-triphosphate; Akt: protein kinase B; GSK3: glycogen synthase kinase 3; mTOR:
  mammalian target of rapamycin; MEK: MAPK kinase; ERK: extracellular signal-regulated
  kinase; JAK: Janus kinase; STAT: signal transducer and activator of transcription.'
papertitle: 'Targeting EGFR signalling in chronic lung disease: therapeutic challenges
  and opportunities.'
reftext: Sabari Vallath, et al. Eur Respir J. ;44(2):513-522.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9604328
figid_alias: PMC4209854__F3
figtype: Figure
organisms_ner:
- NA
redirect_from: /figures/PMC4209854__F3
ndex: c2673bff-deba-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4209854__emss-60583-f0003.html
  '@type': Dataset
  description: 'Three strategies are used to antagonise aberrant EGFR signalling.
    First, monoclonal antibodies bind the extracellular domain of epidermal growth
    factor (EGF) receptors and prevent endogenous ligand engagement, thereby attenuating
    downstream pathway activation (cetuximab and trastuzumab). Secondly, small molecule
    tyrosine kinase inhibitors target the intracellular portion of EGF receptors;
    in the absence of kinase activity EGFR autophosphorylation and downstream signalling
    is inhibited (erlotinib, gefitinib, lapatinib, HKI-272 and BIBW-2948). Finally,
    small molecule inhibitors which target specific downstream EGFR signalling pathway
    components have also been developed and may exhibit clinical efficacy in chronic
    respiratory disease (ARRY-142886, PX-866, rapamycin, SDZ RAD, everolimus, ruxolitinib,
    perifosine, selumetinib and sorafenib). PI3K: phosphatidylinositol-3-kinase; PIP3:
    phosphatidylinositol (3,4,5)-triphosphate; Akt: protein kinase B; GSK3: glycogen
    synthase kinase 3; mTOR: mammalian target of rapamycin; MEK: MAPK kinase; ERK:
    extracellular signal-regulated kinase; JAK: Janus kinase; STAT: signal transducer
    and activator of transcription.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Perifosine
  - ARRY-142886
  - Selumetinib
  - Ruxolitinib
  - Rapamycin
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
